A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment (CheckMate 744)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02927769

Recruitment Status : Recruiting

First Posted : October 7, 2016

Last Update Posted : June 11, 2020

See Contacts and Locations

Sponsor:

Collaborator:

Seagen Inc.

Information provided by (Responsible Party):

Bristol-Myers Squibb

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	March 27, 2023
Estimated Study Completion Date :	March 27, 2024

To Top